SCHEMBL92828

SCHEMBL92828

O=CNS(=O)(=O)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.56
CA2 P00918 2/20 0.56
MMP1 P03956 1/20 0.56
MMP2 P08253 1/20 0.56
MMP9 P14780 1/20 0.56
MMP8 P22894 1/20 0.56
MMP13 P45452 1/20 0.56
KEAP1 Q14145 3/20 0.54
IL1RN P18510 1/20 0.54
ERAP1 Q9NZ08 1/20 0.54
ALDH1A1 P00352 4/20 0.50
PKM P14618 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
HTR6 P50406 1/20 0.48
BCAT1 P54687 2/20 0.46
TLR9 Q9NR96 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2371757 0.83 CA1 (0.54) CA1CA2MMP1MMP2MMP9
SCHEMBL6853234 0.79 HTR6 (0.42) CA1CA2MMP1MMP2MMP9
SCHEMBL423688 0.79 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL423265 0.79 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL17764 0.79 GAA (0.59) CA1CA2MMP1MMP2MMP9
SCHEMBL11697966 0.79 BCAT1 (0.50) CA1CA2MMP1MMP2MMP9
SCHEMBL9135659 0.79 CA2 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL11751509 0.79 CA1 (0.57) CA1CA2MMP1MMP2MMP9
SCHEMBL8824913 0.79 F2 (0.53) CA1CA2ALDH1A1KMT2AHSD17B10
SCHEMBL2372569 0.78 CA2 (0.54) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-05-12 US claimed
CN-104640847-B Novel Renin Inhibitors 上海医药集团股份有限公司 2019-10-15 CN claimed
US-20180282289-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST DAIICHI SANKYO COMPANY, LIMITED (JP) 2018-10-04 US claimed
EP-3380970-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST Sanford Burnham Prebys Medical Discovery Institute (US) 2018-10-03 EP claimed
EP-2933248-B1 NOVEL RENIN INHIBITOR MITSUBISHI TANABE PHARMA CORP (JP) 2018-01-31 EP claimed
US-9758480-B2 1-(cycloalkyl-carbonyl)proline derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-09-12 US claimed
US-9556159-B2 Renin inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-31 US claimed
CN-103483270-B A kind of synthetic method of 2-(4,6-dimethyl pyrimidine-2-base carbamoylamino alkylsulfonyl) methyl benzoate XI'AN INST. OF MODERN CHEMISTRY (CN) 2016-03-02 CN claimed
US-20150344877-A1 METHODS FOR TREATING VIRAL INFECTIONS PTC THERAPEUTICS, INC. (US) 2015-12-03 US claimed
EP-2933248-A1 NOVEL RENIN INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2015-10-21 EP claimed
US-5001138-A Insecticides NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) 1991-03-19 US claimed
US-4968695-A NEMATOCIDES, LARVICIDES BAYER AKTIENGESELLSCHAFT (DE) 1990-11-06 US claimed
EP-0335315-A1 New alkanephenones CIBA-GEIGY AG (CH) 1989-10-04 EP claimed
US-4845106-A INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1989-07-04 US claimed
EP-0292822-A2 Substituted nitroalkenes BAYER AG (DE) 1988-11-30 EP claimed
EP-0272671-A2 Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors SANDOZ LTD. (CH) 1988-06-29 EP claimed
US-4742060-A 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) 1988-05-03 US claimed
US-4410522-A BACTERICIDES TOYAMA CHEMICAL CO., LTD. (JP) 1983-10-18 US claimed
US-4327097-A BACTERICIDES FOR MAMMALS TOYAMA CHEMICAL CO., LTD. (JP) 1982-04-27 US claimed
US-4219554-A Novel penicillins and cephalosporins and process for producing same TOYAMA CHEMICAL COMPANY, LIMITED (JP) 1980-08-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144784-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 CA1 2295/4885CA2 436/4885MMP1 1941/4885
US-20180282289-A1 NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST APLNR, AGTR1, AGTR2 CA1 2276/4885CA2 438/4885MMP1 1928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.